CareDx completes Clinical Laboratory Improvement Amendments validation of AlloMap Kidney
CareDx Inc. announced in a press release that its AlloMap Kidney completed the Clinical Laboratory Improvement Amendments validation, allowing it to move forward for a commercial launch.
AlloMap Kidney is designed to be a blood-based gene expression classifier that determines immune quiescence in kidney transplant patients. Researchers tested AlloMap in a clinical trial published in Kidney360 and showed its ability to differentiate between rejection and antibody-medicated rejection and immune quiescence.
“We are pleased to have completed [Clinical Laboratory Improvement Amendments] CLIA validation of AlloMap Kidney on schedule and to be moving a step closer to the commercialization of KidneyCare, a breakthrough multimodality solution that will help clinicians more comprehensively monitor the organ health of their kidney transplant patients,” Reg Seeto, CEO and president of CareDx, said in the release.
Read more about